Loading...
•
Jun 30, 2020
Akero Q2 2020 Earnings Report
Akero Therapeutics reported second quarter financial results for the period ending June 30, 2020.
Key Takeaways
Akero Therapeutics reported positive histological results for their FGF21 analog, efruxifermin (EFX), observing improvements in NASH histological parameters after 16 weeks of treatment. Clinically meaningful improvements in glycemic control, weight loss, and lipoproteins were also observed in the BALANCED study.
Reported first histological results for efruxifermin (EFX).
Observed improvements in histological parameters of NASH after only 16 weeks of treatment.
Observed significant reductions in HbA1c and body weight in biopsy-confirmed NASH patients following EFX treatment.
Observed significant 12-14% absolute reductions (corresponding to 63-72% relative reductions) in liver fat.
Forward Guidance
Akero is dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...